$0.740
-0.047 (-6.37%)終値時点
OCGN のニュース
OCGN のイベント
Significant Increases in Indicative Borrow Rates for Liquid Options
Latest data shows the largest indicative borrow rate increases among liquid option names include: Tradr 2X Long LITE Daily ETF (LITX) 30.74% +3.26, GraniteShares 2x Short SpaceX Daily ETF (SNK) 83.57% +1.09, Beyond Meat (BYND) 26.11% +0.66, Ocugen (OCGN) 4.08% +0.48, T-REX 2X LONG MSTR DAILY TARGET (MSTU) 15.63% +0.24, Rezolve AI Ltd (RZLV) 43.99% +0.24, ProShares UltraShort Lehman 20 plus Year Treasury (TBT) 7.88% +0.17, Analog Devices (ADI) 0.41% +0.16, iShares Silver Trust (SLV) 0.43% +0.16, and Draganfly (DPRO) 15.84% +0.16.
Ocugen Signs Exclusive License Agreement for OCU400 with Roots Pharmaceutical
Ocugen announced the execution of a licensing agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen's novel modifier gene therapy for the treatment of Retinitis Pigmentosa, in the Middle East and North Africa region. Subject to the terms of the License Agreement, Ocugen will receive an upfront license fee and potential initial development milestone payments of up to $4M, in the aggregate, as well as potential sales milestone payments of up to $255M, and royalties equaling 22% of OCU400 net sales generated by Roots Pharmaceutical. Ocugen will manufacture the commercial supply of OCU400 under terms of a related supply agreement.
Applix Inc. Borrow Rate Increases to 12.22%
Latest data shows the largest indicative borrow rate increases among liquid option names include: Applix Inc. (APLX) 12.22% +0.93, T-REX 2X LONG MSTR DAILY TARGET (MSTU) 17.18% +0.93, Direxion Daily 20 plus Year Treasury Bear 3X Shares (TMV) 45.22% +0.93, FingerMotion (FNGR) 32.41% +0.91, Canadian Solar (CSIQ) 2.40% +0.52, Ocugen (OCGN) 3.27% +0.50, InMode (INMD) 0.73% +0.46, Defiance Daily Target 2X Long RGTI ETF (RGTX) 34.44% +0.44, Defiance Daily Target 2X Long RKLB ETF (RKLX) 20.33% +0.33, and Americas Silver (USAS) 1.34% +0.32.
Ocugen's OCU400 Receives Provisional Approval from LARTA in The Bahamas
Ocugen announced that OCU400 has been granted provisional approval and priority designation from the LARTA Board, the regulatory agency responsible for reviewing and approving longevity and regenerative therapy programs within the Commonwealth of The Bahamas. Ocugen will supply OCU400 through an EAP, with the goal of treating the first RP patient within 90 days, following full LARTA approval. "Our partnership marks an important milestone for Ocugen - creating a unique opportunity to provide global access through the Bahamas to OCU400 for people suffering from retinitis pigmentosa," said Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen. "This landmark collaboration demonstrates the potential of our differentiated gene therapy platform and represents an exciting step toward expanding the reach of our innovative, one-time treatments for patients with serious retinal diseases."
Ocugen Doses First Patient in OCU410 Phase 3 Trial
Ocugen announced that the first patient was dosed in the global Phase 3 registrational trial of OCU410, its modifier gene therapy candidate for GA secondary to dry age-related macular degeneration. The company also highlighted the recent FDA RMAT designation for OCU410, which supports a potential accelerated development and review pathway for the program.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。